Activation of Akt as a mechanism for tumor immune evasion

Molecular Therapy

Volumn 17, Issue 3, 2009, Pages 439-447

  Noh, Kyung Hee ^a   Kang, Tae Heung ^a   Kim, Jin Hee ^a   Pai, Sara I ^b   Lin, Ken Y ^c   Hung, Chien Fu ^b   Wu, T C ^b   Kim, Tae Woo ^a  

^a Korea University College of Medicine   (South Korea)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PROTEIN E7; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RETROVIRUS VECTOR; VACCINIA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INVASION; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; TUMOR; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CHLORPROPAMIDE; ENZYME ACTIVATION; FEMALE; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS; PHENOTYPE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; VACCINATION;

HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 61649110680     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.255     Document Type: Article

References (20)

1. Rosenberg, SA, Yang, JC and Restifo, NP (2004). Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915.
2. Lin, KY, Guarnieri, FG, Staveley-O'Carroll, KF, Levitsky, HI, August, JT, Pardoll, DM et al. (1996). Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26.
3. Wu, TC (2007). The role of vascular cell adhesion molecule-1 in tumor immune evasion. Cancer Res 67: 6003-6006.
4. Wu, TC, Guarnieri, FG, Staveley-O'Carroll, KF, Viscidi, RP, Levitsky, HI, Hedrick, L et al. (1995). Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 92: 11671-11675.
5. Lin, KY, Lu, D, Hung, CF, Peng, S, Huang, L, Jie, C et al. (2007). Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res 67: 1832-1841.
6. Kim, S, Jee, K, Kim, D, Koh, H and Chung, J (2001). Cyclic AMP inhibits Akt activity by blocking the membrane localization of PDK1. J Biol Chem 276: 12864-12870.
7. Kohn, AD, Summers, SA, Birnbaum, MJ and Roth, RA (1996). Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 271: 31372-31378.
8. Yang, L, Dan, HC, Sun, M, Liu, Q, Sun, XM, Feldman, RI et al. (2004). Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 64: 4394-4399.
9. West, KA, Castillo, SS and Dennis, PA (2002). Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5 234-248.
10. Kim, TJ, Lee, JW, Song, SY, Choi, JJ, Choi, CH, Kim, BG et al. (2006). Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer 94: 1678-1682.
11. Hahnel, PS, Thaler, S, Antunes, E, Huber, C, Theobald, M and Schuler, M (2008). Targeting AKT signaling sensitizes cancer to cellular immunotherapy. Cancer Res 68: 3899-3906.
12. Cheng, JQ, Lindsley, CW, Cheng, GZ, Yang, H and Nicosia, SV (2005). The Akt/PKB pathway: Molecular target for cancer drug discovery. Oncogene 24: 7482-7492.
13. Han, HD, Song, CK, Park, YS, Noh, KH, Kim, JH, Hwang, T et al. (2008). A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine. Int J Pharm 350: 27-34.
14. Kim, D, Kim, S, Koh, H, Yoon, SO, Chung, AS, Cho, KS et al. (2001). Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. Faseb J 15: 1953-1962.
15. Huang, CH, Peng, S, He, L, Tsai, YC, Boyd, DA, Hansen, TH et al. (2005). Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther 12: 1180-1186.
16. Wang, TL, Ling, M, Shih, IM, Pham, T, Pai, SI, Lu, Z et al. (2000). Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 7: 726-733.
17. Hung, CF, Cheng, WF, He, L, Ling, M, Juang, J, Lin, CT et al. (2003). Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res 63 2393-2398.
18. Cheng, WF, Hung, CF, Chai, CY, Hsu, KF, He, L, Ling, M et al. (2001). Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108: 669-678.
19. Chen, CH, Wang, TL, Hung, CF, Yang, Y, Young, RA, Pardoll, DM et al. (2000). Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60: 1035-1042.
20. Hung, CF, Cheng, WF, Hsu, KF, Chai, CY, He, L, Ling, M et al. (2001). Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 61: 3698-3703.